In The News
Top 10 class action settlements of 2024
High Court asked to weigh in on Katy Perry trade mark stoush
Toyota unit Hino to pay $87M to settle emissions cheating class action
Tougher penalties floated for improper legal privilege claims
Dominique Grubisa, Master Wealth lose challenge to $6M penalty
‘Considerable disquiet’: Pelvic mesh group members can challenge $405M settlements
Judge rejects sacked Super Retail Group execs’ settlement claims
$56M settlement approved in Monash IVF class action
Kids clothing retailer hit with $5M penalty for worker exploitation
Third person sentenced over $180M Courtenay House Ponzi scheme
Please login to bookmarkClose

GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au